Ptc Therapeutics Stock Price, News & Analysis

PTC Therapeutics has entered a strategic financing collaboration with Blackstone, securing up to $500 million in funding to enhance its product pipeline and business development. This includes $350 million in low-cost capital at the close. The funds will help accelerate PTC's mission to deliver transformative medicines, with a goal of launching one therapy every 2-3 years. Blackstone's investment will be collateralized by PTC's existing products, including Translarna™ and Upstaza®. The collaboration aims to optimize capital structure and support new medicines.

PTC Therapeutics (NASDAQ: PTCT) has confirmed ongoing enrollment for its Phase 2 PIVOT-HD trial of PTC518, aimed at treating Huntington's disease. The 12-month study has received approval in several European countries and Australia, focusing on two dose levels: 5mg and 10mg. Enrollment began in the US but has paused due to FDA requests for additional data. There have been no treatment-related adverse events reported to date. PTC plans to share data from the initial 12-week study phase within the first half of 2023.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on October 27, 2022, at 4:30 p.m. ET to discuss its third quarter 2022 financial results and business updates. Participants can register for the call online to receive dial-in details and are advised to join 15 minutes early. A replay will be available approximately two hours after the call and can be accessed on the company's website for 30 days. PTC is focused on developing medicines for rare disorders, leveraging its scientific expertise and global commercial capabilities.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will present new data on Translarna™ (ataluren) at the 27th International Annual Congress of the World Muscle Society in Halifax, Nova Scotia, on October 12-14, 2022. Key presentations will highlight updated demographics and safety data, age at loss of ambulation, pulmonary function, and the efficacy of ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Translarna is currently licensed in the European Economic Area for nmDMD treatment in ambulatory patients aged 2 and older, while being investigational in the U.S.

PTC Therapeutics (NASDAQ: PTCT) announced the recipients of its 2022 STRIVE Awards, supporting Duchenne Muscular Dystrophy initiatives. The program grants funds to four organizations: ACDM (Brazil) for educational rehabilitation, KASDER (Turkey) for expanding psychological services, MDA Hellas (Greece) for a film on sexuality, and Action Duchenne (U.K.) for skills training. This year, PTC received 40 applications, highlighting diverse needs in the Duchenne community. The STRIVE Awards enhance awareness and support for patients, aiming to provide a broader impact across four countries.

PTC Therapeutics (NASDAQ: PTCT) will present an overview at upcoming investor conferences: Wells Fargo's 17th Annual Healthcare Conference on Sept. 8 at 1:55 p.m. EDT and Morgan Stanley's 20th Annual Global Healthcare Conference on Sept. 12 at 4:15 p.m. EDT. These presentations will be available via live webcast on PTC's Investor page and archived for 30 days. PTC focuses on developing treatments for rare disorders, enhancing access to innovative medicines for patients with unmet medical needs.

PTC Therapeutics reported $166 million in total revenue for Q2 2022, marking a 42% year-over-year growth. The DMD franchise showed strong revenue performance with $134 million net product revenue, a 32% increase from the previous year. Notably, Upstaza™ gene therapy received marketing authorization from the European Commission, beginning its commercial rollout. However, the company faced a net loss of $152 million compared to $118 million in Q2 2021. PTC reaffirms its full-year guidance of $700-$750 million in total revenues.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on August 4, 2022, at 4:30 p.m. ET, to discuss its second quarter 2022 financial results and provide a business outlook. Participants can register for the call in advance to receive dial-in details and are encouraged to join 15 minutes early to avoid delays. A replay of the conference call will be available on PTC's website shortly after the event and archived for 30 days. The company is committed to developing treatments for rare disorders.

PTC Therapeutics announced the European Commission's approval of Upstaza™ (eladocagene exuparvovec), the first gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, applicable in all EU member states and select countries. This therapy is significant for patients aged 18 months and older, offering a disease-modifying treatment option. Clinical trials showed substantial improvements in motor and cognitive skills in treated patients. CEO Stuart W. Peltz emphasized the therapy's potential impact on the quality of life for patients suffering from this severe genetic disorder.